Correlation of IDH1 Mutation with Clinicopathologic Factors and Prognosis in Primary Glioblastoma: A Report of 118 Patients from China
Open Access
- 23 January 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (1), e30339
- https://doi.org/10.1371/journal.pone.0030339
Abstract
It has been reported that IDH1 (IDH1R132) mutation was a frequent genomic alteration in grade II and grade III glial tumors but rare in primary glioblastoma (pGBM). To elucidate the frequency of IDH1 mutation and its clinical significance in Chinese patients with pGBM, one hundred eighteen pGBMs were assessed by pyro-sequencing for IDH1 mutation status, and the results were correlated with clinical characteristics and molecular pathological factors. IDH1 mutations were detected in 19/118 pGBM cases (16.1%). Younger age, methylated MGMT promoter, high expression of mutant P53 protein, low expression of Ki-67 or EGFR protein were significantly correlated with IDH1 mutation status. Most notably, we identified pGBM cases with IDH1 mutation were mainly involved in the frontal lobe when compared with those with wild-type IDH1. In addition, Kaplan-Meier survival analysis revealed a highly significant association between IDH1 mutation and a better clinical outcome (p = 0.026 for progression-free survival; p = 0.029 for overall survival). However, in our further multivariable regression analysis, the independent prognostic effect of IDH1 mutation is limited when considering age, preoperative KPS score, extent of resection, TMZ chemotherapy, and Ki-67 protein expression levels, which might narrow its prognostic power in Chinese population in the future.Keywords
This publication has 25 references indexed in Scilit:
- Gene expression profiling reveals Ki-67 associated proliferation signature in human glioblastoma.2011
- Oncogene addiction in gliomas: Implications for molecular targeted therapyJournal of Experimental & Clinical Cancer Research, 2011
- DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in GliomaJNCI Journal of the National Cancer Institute, 2011
- IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomasNeurology, 2010
- Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of GliomaCancer Cell, 2010
- Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancerBreast Cancer Research, 2006
- The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphomaBlood, 2006
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005
- Review of epidermal growth factor receptor biologyInternational Journal of Radiation Oncology*Biology*Physics, 2004
- Restoring p53-Dependent Tumor SuppressionCancer Biology & Therapy, 2003